[Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) - Benefit assessment according to §35a Social Code Book V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004310
German
Original Title:
Lisocabtagen maraleucel (DLBCL, PMBCL, FL3B)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a22-90.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a22-90_lisocabtagen-maraleucel_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Follicular
- Antigens, CD19
- Immunotherapy, Adoptive
- Receptors, Chimeric Antigen
Keywords
- Lisocabtagene maraleucel
- Lymphoma - Large B-Cell - Diffuse
- Lymphoma - Follicular
- Benefit Assessment
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.